缺氧诱导因子1在肿瘤细胞免疫逃避中的作用

doi:10.16098/j.issn.0529-1356.2016.06.025

摘要/Abstract

摘要：

缺氧是肿瘤的重要特征。在肿瘤发生过程中，缺氧诱导因子1是协调缺氧变化的重要的调节因子。缺氧和缺氧诱导因子1可以调节肿瘤内的免疫应答，缺氧通过激活缺氧诱导因子1 及其下游信号通路诱导肿瘤细胞产生多种机制以逃避免疫系统的识别和攻击。作者主要综述了缺氧诱导因子1介导的肿瘤免疫逃避，以及针对缺氧诱导因子1靶向药物的开发。

关键词: 缺氧诱导因子1, 肿瘤, 免疫逃避

Abstract:

Hypoxia is a hallmark of tumor, and hypoxia-inducible factor (HIF-1) is an essential regulator of hypoxia adaptation in tumor progression. Hypoxia and HIF-1 signaling are important components of the tumor microenvironment that modulates the tumor immune response. Tumor hypoxia via HIF-1 signaling enables tumor cell to develop mechanisms to evade from immune surveillance and attack. This mini-review emphasizes on the molecular mechanisms of HIF-1-mediated tumor cell escape and the development of inhibitors targeting HIF-1.

Key words: Hypoxia-inducible factor 1, Tumor, Immune escape

熊伟鹏. 缺氧诱导因子1在肿瘤细胞免疫逃避中的作用[J]. 解剖学报, 2016, 47(6): 859-961.

XIONG Wei-peng. Role of hypoxia-inducible factor-1 in immune escape of tumor cells[J]. Acta Anatomica Sinica, 2016, 47(6): 859-961.

参考文献

［1］LaGory EL, Giaccia AJ. The ever-expanding role of HIF in tumour and stromal biology ［J］. Nat Cell Biol, 2016, 18(4):356-365.

［2］Rankin EB, Giaccia AJ. Hypoxic control of metastasis ［J］. Science, 2016, 352(6282):175-180.

［3］Pouyssequr J, Dayan F, Mazure NM. Hypoxia signaling in cancer and approaches to enforce tumour regression ［J］. Nature, 2006, 441(7092):437-443.

［4］Barsoum IB, Koti M, Siemens DR, et al. Mechanisms of hypoxia-mediated immune escape cancer ［J］. Cancer Res, 2014, 74(24):7185-7190.

［5］Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects ［J］. Nat Rev Immunol, 2004, 4(12):941-952.

［6］Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment ［J］. Carcinogenesis, 2009, 30(3):377-386.

［7］Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression ［J］. Cancer Meta Rev, 2007, 26(3-4):525-534.

［8］Whiteside TL, Mandapathil M, Schuler P. The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg) ［J］. Curr Med Chem, 2011, 18(34):5217-5223.

［9］Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor ［J］. J Clin Invest, 2003, 111(5):727-735.

［10］Serafini P, Mgebroff S, Noonan K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells ［J］. Cancer Res, 2008, 68(13):5439-5449.

［11］Barsoum IB, Hamilton TK, Li X, et al. Hypoxia induces escape from innate immunity in cancer cells viaincreased expression of ADAM10: role of nitric oxide ［J］. Cancer Res, 2011, 71(24):7433-7441.

［12］Barsoum IB, Smallwood CA, Siemens DR, et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells ［J］. Cancer Res, 2014, 74(3):665-674.

［13］Wu AA, Drake V, Huang HS, et al. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells ［J］. Oncoimmunology, 2015, 4(7):1-14.

［14］Medina PJ, Adams VR. PD-1 pathway inhibitors: immune-oncology agents for restoring antitumor immune responses ［J］. Pharmacotherapy, 2016, 36(3):317-334.

［15］Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications ［J］. Nat Rev Clin Oncol, 2016, 13(4):209-227.

［16］Zhang H, Lu H, Xiang L, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells ［J］. Proc Natl Acad Sci USA, 2015, 112(45):E6215-6223.

［17］Jardon MA, Rothe K, Bortnik S, et al. Autophagy: from structure to metabolism to therapeutic regulation ［J］. Autophagy, 2013, 9(12):2180-2182.

［18］Paggetti J, Viry E, Berchem G, et al. Hypoxia-induced autophagy in tumor cells: a key target for improving cancer immunotherapy ［J］. Cancer Cell & Microenviron, 2014, 1(e213):1-5.

［19］Ajdukovic J. HIF-1-a big chapter in the cancer tale ［J］. Exp Oncol, 2016, 38(1):9-12.

［20］Miranda E, Nordgren IK, Male AL, et al. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells ［J］. J Am Chem Soc, 2013, 135(28):10418-10425.

［21］Masoud GN, Li W. HIF-1αpathway: role, regulation and intervention for cancer therapy ［J］. Acta Pharm Sin B, 2015, 5(5):378-389.

［22］Zhao T, Ren H, Jia L, et al. Inhibition of HIF-1αby PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma ［J］. Oncotarget, 2015, 6(4):2250-2262.

［23］Santoni M, Pantano F, Amantini C, et al. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma ［J］. Biochim Biophys Acta, 2014, 1845(2):221-231.

［24］Karim SM, Zekri J. Chemotherapy for small cell lung cancer: a comprehensive review ［J］. Oncol Rev, 2012, 6(1):16-36.

［25］Trafalis DT, Alifieris C, Stathopoulos GP, et al. Phase Ⅱ study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer ［J］. Cancer Chemother Pharmacol, 2016, 77(4):713-722.

[1]	侯翌葳杨宇王博段英涛姚宏波. 普兰林肽对5×FAD小鼠和WT小鼠认知行为及脑和视网膜β淀粉样蛋白6E10、炎症因子和神经细胞形态的影响[J]. 解剖学报, 2023, 54(3): 283-288.
[2]	张圆时萌萌贺嘉贝吴琼钟小林向宇燕徐杨何洁 . 慢性束缚应激对小鼠海马N6甲基腺苷及相关酶表达的影响[J]. 解剖学报, 2023, 54(2): 142-148.
[3]	张润恒杨翠珠李诗琪王姝涵王欣刘靖马宇昕. 石菖蒲挥发油对炎性痛大鼠脊髓背角中胶质纤维酸性蛋白、c-Jun氨基末端蛋白激酶和肿瘤坏死因子α表达的影响[J]. 解剖学报, 2023, 54(1): 23-29.
[4]	姬光瑜周娟李心悦郝洪波. 多梳家族因子1对结直肠癌干细胞富集的影响及其机制[J]. 解剖学报, 2022, 53(5): 613-619.
[5]	李伟杨赣军彭建安胡红梅周星辰. 低氧化应激下肿瘤坏死因子α过表达对牙髓干细胞生物学性能的影响[J]. 解剖学报, 2022, 53(1): 66-74.
[6]	谭学明赵冉孙永珍高晓炎招鹏王燕朱敏李卫东. 超声内镜精准评估肿瘤起源及组织学特征可提高食管平滑肌瘤的手术疗效[J]. 解剖学报, 2021, 52(6): 966-971.
[7]	苏昊任捷秦丽华. Nogo-B受体在恶性实体肿瘤发病中的抑制和促进作用[J]. 解剖学报, 2021, 52(3): 489-494.
[8]	阴雪妍郭哨恺谭军范文统李明. 腺苷预处理对大鼠脑缺血-再灌注损伤后脑内肿瘤坏死因子α和核因子κB表达的影响[J]. 解剖学报, 2020, 51(6): 839-847.
[9]	吴邢檀梦天覃晓莉洪艳. 神经元素3基因沉默对脐源性胰岛前体细胞MafA表达的影响[J]. 解剖学报, 2020, 51(5): 758-764.
[10]	林晨马琪王萍 . 冠蛋白:肿瘤诊断的潜在靶点[J]. 解剖学报, 2020, 51(3): 461-468.
[11]	刘亚军王旋胡海桂艳. 瑞舒伐他汀预处理对缺血再灌注大鼠大脑中动脉血管平滑肌细胞炎症因子的影响及其机制[J]. 解剖学报, 2019, 50(6): 713-717.
[12]	陈麒黄荷淼葛晨涛付彩云. P物质/神经激肽1受体系统在肿瘤治疗中的研究进展[J]. 解剖学报, 2019, 50(6): 861-864.
[13]	卞晓翠刘玉琴杨振丽冯海凉. 国内建立的人肿瘤细胞系的身份认证问题及对策[J]. 解剖学报, 2019, 50(2): 201-210.
[14]	常书锋杨波郑鲁付战胜杨万敬黄晓峰王俊善刘昌. 枕下乙状窦后锁孔经岩裂-桥脑裂入路的显微解剖学[J]. 解剖学报, 2018, 49(5): 646-650.
[15]	许向亮孙志鹏王佃灿王建伟张卫光. 肿瘤发生相关的腮腺体表分区的临床解剖[J]. 解剖学报, 2018, 49(1): 75-80.